Perry Drug Recalls Cyclosporine Eye Drops Due to Sterility Concerns
Perry Drug Inc. is recalling Cyclosporine 0.045% eye drops due to potential sterility assurance issues identified during an FDA inspection.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of sterility assurance in a sterile product, which carries a significant risk of serious injury or infection.
Plain-English summary
Perry Drug Inc. is recalling all lots of sterile products compounded by the pharmacy that are within their expiration date. This recall specifically includes Cyclosporine 0.045% Sol PF, 12 mL bottles, distributed in Kansas and Missouri.
The recall was initiated due to concerns regarding quality control procedures that present a potential risk to sterility assurance. These concerns were observed during a recent FDA inspection.
Consumers who have these products should stop using them and contact their healthcare provider or the recalling firm for instructions on return or disposal.
The recalled product
- Product
- Cyclosporine 0.045 % Sol PF, 12 mL bottle, Rx, Perry Drug Compounding Pharmacy, Overland Park, KS --- NDC 88888-5120-67
- Manufacturer
- Perry Drug Inc.
- Category
- Drug — Ophthalmic
- Affected units
- 3
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- 141013CC
- 11/13/14
Distribution
Part of a larger recall action
This product is one of 17 recalled by Perry Drug Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 17 products in this recall →Related recalls
Same manufacturer · Perry Drug Inc.
See all →- SeverePerry Drug Recalls Tri-mix Antidote Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls HCG Vials Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls Methyl B12 Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls Phenylephrine Syringes Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
- SeverePerry Drug Recalls HCG Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2014-12-03
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- SevereWestern Drug Recalls Cyclosporine Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2015-12-09
- SevereEssential Wellness Pharma Recalls Cyclosporin Eye Drops Due to Sterility Concerns
FDA (Drugs) · 2015-11-25
- HighPharmacy Innovations Cyclosporine Eye Drops Recalled for Sterility Defect
FDA (Drugs) · 2023-02-01
- SevereCyclosporine 1% Ophthalmic Drops Recalled for Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereCyclosporine 2% Ophthalmic Recalled Due to Sterility Concerns
FDA (Drugs) · 2013-07-10
- SevereNorthwest Compounding Pharmacy Recalls Cyclosporin Liquid Due to Sterility Concerns
FDA (Drugs) · 2019-01-09